Reduced Expression Levels of the MST1 gene in the Peripheral Blood of Patients with Prostate Cancer

Fariba Karimian, M. Sahmani, Amirhosein Maali, T. Farivar, A. Karimi, M. Azad
{"title":"Reduced Expression Levels of the MST1 gene in the Peripheral Blood of Patients with Prostate Cancer","authors":"Fariba Karimian, M. Sahmani, Amirhosein Maali, T. Farivar, A. Karimi, M. Azad","doi":"10.18502/BCCR.V11I1.1648","DOIUrl":null,"url":null,"abstract":"Background: Prostate cancer (PC) is the second most common malignancy among men, accounting for 12.5% of all cancers. The development of molecular studies (such as RNA expression analysis) aids the characterization of this cancer, the development of new targets for therapy, and the introduction of novel prognostic and diagnostic biomarkers. Recent studies have confirmed Mammalian Sterile 20-Like kinase (MST1) as a tumor suppressor gene, which has been introduced as a biomarker for some specific cancers. In this study, we focus on MST1 expression levels in the WBC of PC patients, due to the inheritance pattern of PC. Methods: This case-control study was conducted in two groups (20 patients with PC and 20 healthy individuals). After RNA extraction and cDNA synthesis, quantitative Real-Time PCR was done in order to determine the MST1 expression level. GAPDH was selected as an internal control gene. Statistical analysis was performed using “Rotor-Gene Q series software 2.3.1” and “Rest 2.0.13 software”. Results: This study, carried out on 20 PC patients aged 50-70 and 20 healthy individuals shows that MST1 expression level in the WBC samples of PC patients is approximately 62% lower compared to normal individuals (P<0.01). Conclusion: Introducing the reduced expression level of MST1 as a prostate cancer biomarker requires complementary research. However, in this study, biomarker validation and potential of MST1 has been approved.","PeriodicalId":8706,"journal":{"name":"Basic & Clinical Cancer Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/BCCR.V11I1.1648","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prostate cancer (PC) is the second most common malignancy among men, accounting for 12.5% of all cancers. The development of molecular studies (such as RNA expression analysis) aids the characterization of this cancer, the development of new targets for therapy, and the introduction of novel prognostic and diagnostic biomarkers. Recent studies have confirmed Mammalian Sterile 20-Like kinase (MST1) as a tumor suppressor gene, which has been introduced as a biomarker for some specific cancers. In this study, we focus on MST1 expression levels in the WBC of PC patients, due to the inheritance pattern of PC. Methods: This case-control study was conducted in two groups (20 patients with PC and 20 healthy individuals). After RNA extraction and cDNA synthesis, quantitative Real-Time PCR was done in order to determine the MST1 expression level. GAPDH was selected as an internal control gene. Statistical analysis was performed using “Rotor-Gene Q series software 2.3.1” and “Rest 2.0.13 software”. Results: This study, carried out on 20 PC patients aged 50-70 and 20 healthy individuals shows that MST1 expression level in the WBC samples of PC patients is approximately 62% lower compared to normal individuals (P<0.01). Conclusion: Introducing the reduced expression level of MST1 as a prostate cancer biomarker requires complementary research. However, in this study, biomarker validation and potential of MST1 has been approved.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
前列腺癌患者外周血中MST1基因表达水平的降低
背景:前列腺癌(PC)是男性第二常见的恶性肿瘤,占所有癌症的12.5%。分子研究(如RNA表达分析)的发展有助于这种癌症的特征,新的治疗靶点的发展,以及新的预后和诊断生物标志物的引入。近年来的研究证实,哺乳动物不育20样激酶(MST1)是一种肿瘤抑制基因,已被引入作为某些特定癌症的生物标志物。在本研究中,由于PC的遗传模式,我们关注的是MST1在PC患者白细胞中的表达水平。方法:本研究分为两组,分别为20例PC患者和20例健康人。提取RNA和合成cDNA后,进行实时荧光定量PCR检测MST1的表达水平。选择GAPDH作为内控基因。采用“Rotor-Gene Q系列软件2.3.1”和“Rest 2.0.13软件”进行统计分析。结果:本研究对20例50 ~ 70岁的PC患者和20例健康人进行了研究,结果显示,PC患者WBC样本中MST1表达水平比正常人低约62% (P<0.01)。结论:引入MST1的低表达水平作为前列腺癌的生物标志物需要补充研究。然而,在本研究中,MST1的生物标志物验证和潜力已经得到认可。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
16
审稿时长
12 weeks
期刊最新文献
The Effect of Ursodeoxycholic acid and N-acetyl cysteine on Lymphoblast Viability Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects Chronic Myeloid Leukemia in a Young Man with Unusual Presentation of Weight Loss, Bone Pain, and Abdominal Pain Effects of Gold Nanoparticles on Proton Therapy for Breast Cancer Cancer has an Independent Association with Death in Hospitalized Patients with COVID-19: A Single-center Study in Iran
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1